APA (7th ed.) Citation

H, U., K, M., T, K., T, M., K, N., S, W., . . . S, K. (2026). Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: An extended follow-up of the DAVLEC phase 2 trial. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01526-7

Chicago Style (17th ed.) Citation

H, Ureshino, et al. "Long-term Outcomes of Low-dose Dasatinib in Older Patients with Chronic Myeloid Leukemia in Chronic Phase: An Extended Follow-up of the DAVLEC Phase 2 Trial." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01526-7.

MLA (9th ed.) Citation

H, Ureshino, et al. "Long-term Outcomes of Low-dose Dasatinib in Older Patients with Chronic Myeloid Leukemia in Chronic Phase: An Extended Follow-up of the DAVLEC Phase 2 Trial." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01526-7.